eBooks

eBook: Worldwide, almost 20 million people are diagnosed with cancer each year. While precision-guided cancer management has demonstrated improved outcomes up to threefold, access to precision oncology testing, such as liquid biopsy, remains limited.

In this eBook, sponsored by Qiagen, we explore the opportunities and challenges of precision oncology and how molecular profiling is fundamental not only to inform on tumor diagnosis and prognosis, but also to drive therapeutic decisions in routine clinical care.

The promise of cell and gene therapies to solve some of our most challenging conditions, from rare diseases to cancers, has led this field to remain on the forefront of innovation. Advances in innovative technologies coupled with deeper scientific knowledge in cellular and molecular biology spurred a new era of growth in these advanced therapies.

Today genetic innovation is advancing at breakneck pace. Despite incredible advances in sequencing technology, most notable being next-generation sequencing (NGS), genetic has only recently become a clinical application. The challenge is no longer how to sequence DNA, but how to interpret a patient’s genetic variation in a meaningful and actionable way. In this eBook Qiagen looks at three trends that will change how NGS tests for inherited disorders are analyzed and interpreted in the future.

Oxford Nanopore’s DNA/RNA sequencing technology delivers ultra-long reads (up to 2 Mb), enabling rapid and comprehensive analysis of variants. With devices scalable from portable to benchtop, nanopore sequencing offers a cost-effective solution to the challenges faced by traditional sequencing platforms.

Takeda has taken great strides in incorporating a patient-centric approach to drug development through the use of minimally invasive and less frequent testing procedures while maintaining the power and rigor of the clinical trial.

IsoPlexis’ next generation systems provide actionable potency, safety, and patient difference metrics by detecting highly potent single cell functional subsets for the first time.

Codevelopment is an intermittent and uncertain process. Adopting an agnostic approach to the challenges associated with platform and method selection provide added degrees of freedom for strategic development and selection of the most appropriate clinical trial assay.

In this eBook learn how MolecularMD is harnessing the company's unique capabilities to address diagnostic needs within immuno-oncology.

The challenges of incorporating NGS into clinical trials is being addressed through the adoption of robust technology solutions.